



Chris Stevens, Chief Operating Officer, Rocket Pharma

Chris Stevens is the Chief Operating Officer (COO) of Rocket Pharma, responsible for shaping corporate strategy, scaling operations, and driving business growth. As COO, Chris leads the quality, manufacturing, EHS, and corporate facilities organizations.

Chris is a seasoned executive with 25 years of experience across technical operations, product strategy, and general management. Prior to Rocket, Chris most recently served as Executive Vice President and Chief Patient Supply Officer at Spark Therapeutics, where he successfully led teams across manufacturing, supply chain, quality, compliance, engineering, EHS, and facilities, playing a key role in delivering gene therapies to patients globally.

During his tenure at Spark, he was also Head of Manufacturing through the approval and launch of Luxturna, the first gene therapy approved for a genetic disease in the U.S. and EU. He later served as Asset General Manager for the Hemophilia A program and subsequently Head of Product Strategy, overseeing program development for Spark's entire portfolio.

Prior to Spark, Chris led teams at GlaxoSmithKline focused on strategy, operations, and planning, as well as GMP clinical manufacturing operations including process transfer and cell banking. Earlier in his career he held roles of increasing responsibility at Bristol-Myers Squibb in process engineering, manufacturing and supply chain in Massachusetts, Indiana and Puerto Rico.

Chris received his M.S. in Industrial Management from the University of Southern Indiana and a B.S. in Chemical Engineering from Purdue University.